drugset / Trial / NCT04843033
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors.
Timeline
- Start
- 2021-04-02
- Primary completion
- 2023-10
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SH3809 | Small molecule | 2 mg | Oral |
| Subject | SH3809 | Small molecule | 4 mg | Oral |
| Subject | SH3809 | Small molecule | 6 mg | Oral |
| Subject | SH3809 | Small molecule | 8 mg | Oral |
| Subject | SH3809 | Small molecule | 10 mg | Oral |
| Subject | SH3809 | Small molecule | 12 mg | Oral |